Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-19-006906
Filing Date
2019-05-13
Accepted
2019-05-13 16:06:27
Documents
62
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 597545
2 ex31-1.htm EX-31.1 17947
3 ex31-2.htm EX-31.2 18110
4 ex32-1.htm EX-32.1 7859
5 logo_001.jpg GRAPHIC 17469
  Complete submission text file 0001493152-19-006906.txt   3485400

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE mtnb-20190331.xml EX-101.INS 491310
7 XBRL SCHEMA FILE mtnb-20190331.xsd EX-101.SCH 45087
8 XBRL CALCULATION FILE mtnb-20190331_cal.xml EX-101.CAL 56298
9 XBRL DEFINITION FILE mtnb-20190331_def.xml EX-101.DEF 195193
10 XBRL LABEL FILE mtnb-20190331_lab.xml EX-101.LAB 330511
11 XBRL PRESENTATION FILE mtnb-20190331_pre.xml EX-101.PRE 257507
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-443-1860
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38022 | Film No.: 19818421
SIC: 2834 Pharmaceutical Preparations